<SEC-DOCUMENT>0001193125-21-003641.txt : 20210107
<SEC-HEADER>0001193125-21-003641.hdr.sgml : 20210107
<ACCEPTANCE-DATETIME>20210107061601
ACCESSION NUMBER:		0001193125-21-003641
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20210107
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210107
DATE AS OF CHANGE:		20210107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21392
		FILM NUMBER:		21512943

	BUSINESS ADDRESS:	
		STREET 1:		SPACES SOUTH DOCKLANDS, BLOCK C
		STREET 2:		77 SIR JOHN ROGERSON'S QUAY
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 VK60
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		SPACES SOUTH DOCKLANDS, BLOCK C
		STREET 2:		77 SIR JOHN ROGERSON'S QUAY
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 VK60

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d281965d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:amrn="http://www.amarincorp.com/20210107" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body>
 <div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2021-01-07_to_2021-01-07">AMARIN CORP PLC\UK</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityTaxIdentificationNumber" name="dei:EntityTaxIdentificationNumber" contextRef="duration_2021-01-07_to_2021-01-07">00-0000000</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityAddressPostalZipCode_duration_2021-01-07_to_2021-01-07" name="dei:EntityAddressPostalZipCode" contextRef="duration_2021-01-07_to_2021-01-07">2</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_CityAreaCode" name="dei:CityAreaCode" contextRef="duration_2021-01-07_to_2021-01-07">353 (0)&amp;#160;1</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2021-01-07_to_2021-01-07">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2021-01-07_to_2021-01-07">0000897448</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="amrn-20210107.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2021-01-07_to_2021-01-07"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000897448</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-07</xbrli:startDate> <xbrli:endDate>2021-01-07</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2021-01-07_to_2021-01-07">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of Earliest Event Reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2021-01-07_to_2021-01-07" format="ixt:datemonthdayyearen">January&#160;7, 2021</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">Amarin Corporation plc</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2021-01-07_to_2021-01-07" format="ixt-sec:edgarprovcountryen">England and Wales</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2021-01-07_to_2021-01-07">0-21392</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"> <span style=" -sec-ix-hidden:Hidden_dei_EntityTaxIdentificationNumber">Not applicable</span> </span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(I.R.S. Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2021-01-07_to_2021-01-07">77 Sir John Rogerson&#8217;s Quay</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2021-01-07_to_2021-01-07">Block C</ix:nonNumeric>,</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine3" contextRef="duration_2021-01-07_to_2021-01-07">Grand Canal Docklands</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2021-01-07_to_2021-01-07">Dublin <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2021-01-07_to_2021-01-07">2</ix:nonNumeric></ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCountry" contextRef="duration_2021-01-07_to_2021-01-07" format="ixt-sec:countrynameen">Ireland</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold">Not applicable</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: + <span style=" -sec-ix-hidden:Hidden_dei_CityAreaCode">353</span> 1 <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2021-01-07_to_2021-01-07">6699 020</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Former name or former address, if changed since last report</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2021-01-07_to_2021-01-07" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2021-01-07_to_2021-01-07" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2021-01-07_to_2021-01-07" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2021-01-07_to_2021-01-07" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2021-01-07_to_2021-01-07">American Depositary Shares (ADS(s)), each ADS representing the right to receive one (1)&#160;Ordinary Share of Amarin Corporation plc</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2021-01-07_to_2021-01-07">AMRN</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2021-01-07_to_2021-01-07" format="ixt-sec:exchnameen">NASDAQ Stock Market LLC</ix:nonNumeric></span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (17 CFR <span style="white-space:nowrap">&#167;240.12b-2).</span></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2021-01-07_to_2021-01-07" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;2.02.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Results of Operations and Financial Condition. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;7, 2021, Amarin Corporation plc issued a press release announcing its preliminary 2020 results and 2021 outlook (the &#8220;Press Release&#8221;). A copy of the Press Release is furnished herewith as Exhibit 99.1. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The information in this report furnished pursuant to Item 2.02 shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report. </span></p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:98%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:93%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center">Exhibit<br />No.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Description</td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d281965dex991.htm">Press Release, dated January&#160;7, 2021 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">* * * </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date: January&#160;7, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3">Amarin Corporation plc</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John F. Thero</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">John F. Thero</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">President and Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d281965dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g281965g0107072404599.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amarin Provides Preliminary 2020 Results and 2021 Outlook </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Unaudited 2020 Total Net Revenue Estimated to Be Approximately $610 Million, an Increase of Approximately </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>42% Compared with 2019 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Completion of European Regulatory Review and Submission of China Regulatory Application for VASCEPA<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(icosapent ethyl) Expected in Late January or February 2021 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DUBLIN, Ireland and BRIDGEWATER, N.J., January&nbsp;7, 2021 &#151; Amarin Corporation plc (NASDAQ:AMRN) today provided a business update, including
preliminary unaudited full-year 2020 revenue results. Amarin plans to discuss these results and expectations with investors in connection with the 39th&nbsp;Annual J.P. Morgan Healthcare Conference at which Amarin is scheduled to present on Tuesday,
January&nbsp;12, 2020, at 2:00 pm Eastern time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preliminary (unaudited) 2020 Financial Results </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Record Revenue Levels:</U>&nbsp;Full-year 2020 total net revenue, subject to audit, are expected to be approximately $610&nbsp;million. Despite the impact
of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> this estimated 2020 net revenue expectation represents an increase of approximately 42% compared with full-year 2019 results. This growth was primarily driven by increased prescription levels of
VASCEPA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Liquid Assets:</U>&nbsp;Amarin ended 2020 with more than
$550&nbsp;million in cash and investments, approximately $150&nbsp;million in net accounts receivable and approximately $180&nbsp;million in inventory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>No Debt:</U> At <FONT STYLE="white-space:nowrap">year-end</FONT> 2020, Amarin had no debt, having fully repaid its prior royalty-like debt instrument in
the fourth quarter of 2020, which from 2013 through most of 2020 required approximately 10% of net revenue to be paid against this prior obligation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Management Commentary </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Amarin has the people,
product and resources to expand globally starting with anticipated 2021 VASCEPA regulatory approval and commercial launch in Europe. Our expected growth in Europe and elsewhere overseas will build on our growth and experience in the United
States,&#148; commented John F. Thero, president and chief executive officer. &#147;We intend to build on our strong scientific foundation and medical experience. As patients begin to return for medical care beyond the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> era, we aim to ensure that VASCEPA is increasingly prescribed to help <FONT STYLE="white-space:nowrap">at-risk</FONT> patients. While 2020 was a challenging year, I am thankful to our employees for
the progress they made in countless areas. Their hard work and passion provide a strong foundation from which we will further launch VASCEPA to reduce persistent cardiovascular risk in appropriate patients, or
<FONT STYLE="white-space:nowrap">P-CVR,</FONT> in the United States, Europe and around the world.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Highlights from 2020 and Outlook </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>U.S. Commercial </U></I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin achieved a number of
important commercial milestones in 2020, despite the challenges Amarin faced with <FONT STYLE="white-space:nowrap">COVID-19</FONT> and the November launch of generic icosapent ethyl in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. commercial highlights from 2020 include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Record levels of VASCEPA revenues, prescriptions, prescribers and patients </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Faster prescription growth for VASCEPA as compared to most other cardiovascular drugs that reported positive
outcomes studies in recent years, despite VASCEPA having a lower level of promotional spend than many such drugs </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">VASCEPA growth in 2020 due to <FONT STYLE="white-space:nowrap">COVID-19</FONT> was slower than initially expected
but compares well with the growth in 2020 of peer drugs </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The <FONT STYLE="white-space:nowrap">P-CVR</FONT> indication has quickly garnered the largest part of the market
as approximately 93% of VASCEPA prescriptions based on the most recent data reported to us by IQVIA were for patients with triglyceride (TG) levels below 500 mg/dL </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Further expanded managed care coverage for VASCEPA during 2020 with additional improvements agreed for 2021
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Such increases are consistent with third-party analysis, which found VASCEPA to be cost effective, and with
medical guidelines or recommendations from six leading U.S. medical societies </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Doubled size of sales force (training for this expanded group was completed in March 2020 just before
Amarin&#146;s customer-facing team was temporarily prohibited from conducting <FONT STYLE="white-space:nowrap">in-person</FONT> meetings due to <FONT STYLE="white-space:nowrap">COVID-19)</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Adapted to <FONT STYLE="white-space:nowrap">COVID-19</FONT> protocols with various tele-sales, tele-marketing and
virtual education initiatives as well as training representatives to safely interact with healthcare professionals where possible </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S.
commercial outlook includes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Confidence that millions of <FONT STYLE="white-space:nowrap">at-risk</FONT> patients remain untreated for <FONT
STYLE="white-space:nowrap">P-CVR</FONT> and could benefit from VASCEPA </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Recognition that many <FONT STYLE="white-space:nowrap">at-risk</FONT> patients ceased doctor visits for ordinary
care in 2020 but are likely to return to their doctors for needed care as <FONT STYLE="white-space:nowrap">COVID-19</FONT> risk recedes </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">According to IQVIA, patient visits to medical offices for <FONT STYLE="white-space:nowrap">non-emergency</FONT>
medical care were down approximately 70% in April 2020 during the height of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> with visits steadily increasing thereafter. In December 2020, as a result of a spike in
<FONT STYLE="white-space:nowrap">COVID-19</FONT> cases, patient visits have decreased approximately 50% compared to <FONT STYLE="white-space:nowrap">pre-COVID</FONT> levels. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Following a resurgence of <FONT STYLE="white-space:nowrap">COVID-19</FONT> in recent months, Amarin intends to
reduce spending levels for certain forms of promotion (e.g., television advertisements) in early 2021 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. promotional spending likely to be variable with adjustments upward or downward in response to the changing
impact from <FONT STYLE="white-space:nowrap">COVID-19</FONT> and generic competition </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccine progress is made, along with other mitigating
approaches, Amarin plans to increasingly resume its promotion of VASCEPA for <FONT STYLE="white-space:nowrap">P-CVR</FONT> while continuing to adapt to market changes </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Generic competition launched in November 2020 only for the original indication (TG <U>&gt;</U>500 mg/dL) and is
expected to continue to face supply limits, despite stockpiles of generic product likely created prior to launch </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Variability is expected as patients, pharmacies and payers adjust to the availability, pricing and label of this
generic competition </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Due to the uncertainties regarding <FONT STYLE="white-space:nowrap">COVID-19</FONT> and potential generic supply,
Amarin will continue to withhold 2021 revenue guidance for VASCEPA in the U.S. until there is greater clarity on the impact of these issues </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amarin intends to continue to manage its U.S. commercial operations to expand patient care and enhance profits
from U.S. operations </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Europe </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Europe highlights from 2020 include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Reached Day 180 of the European Medicines Agency, or EMA, centralized regulatory review of VASCEPA assuring that
the United Kingdom is grandfathered into a facilitated review process despite its withdrawal from the European Union </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An expanded recommendation was issued by the European Society of Cardiology regarding use of icosapent ethyl
(U.S. brand name VASCEPA) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Increased the size of the Amarin team in Europe to approximately 50 experienced professionals to support <FONT
STYLE="white-space:nowrap">pre-approval</FONT> and <FONT STYLE="white-space:nowrap">pre-launch</FONT> preparations for VASCEPA in select countries </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Commenced interactions with authorities in select countries regarding VASCEPA market access assuming approval,
noting that more formal proceedings cannot progress until after the product is approved and the label is established </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Made major advances in expanding company-wide systems to support expected commercial launch of VASCEPA in Europe
in 2021 </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Europe outlook includes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Millions of <FONT STYLE="white-space:nowrap">at-risk</FONT> patients could benefit from VASCEPA in Europe
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There are more patients on statins in Europe in aggregate compared to the U.S. and the rate of death from
cardiovascular disease is higher </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Regulatory approval expected in early 2021 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CHMP opinion expected in late January or February 2021 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">EMA approval decision expected within 67 days of CHMP decision </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Market access negotiations anticipated on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis promptly after approval </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Seeking net pricing that equals or exceeds U.S. net pricing with focus on
<FONT STYLE="white-space:nowrap">P-CVR</FONT> indication based on outcomes data in Europe, whereas pricing in the U.S was based on original TG lowering indication </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Launch timing by country dependent on market access (i.e., insurance coverage) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">At a minimum, launch expected in Germany in 2021 after initial product awareness campaign </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Launch in Germany and other countries is anticipated to give priority to specialists (e.g., cardiologists) and to
also include substantial digital educational and promotional initiatives </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Target of approximately 200 employees (or contractors) in the European commercial team by end of 2021
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Rest of World </U></I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rest of
world, or ROW, highlights from 2020 include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">China positive clinical study results reported </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Canada commercial launch of VASCEPA initiated (just prior to slowdown from
<FONT STYLE="white-space:nowrap">COVID-19)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Canada reimbursement levels for VASCEPA established within six months of product regulatory approval to
facilitate treating patients with established cardiovascular disease </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ROW outlook includes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Large <FONT STYLE="white-space:nowrap">at-risk</FONT> patient opportunities </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In China 290&nbsp;million people are reported to have cardiovascular disease, a number which has been increasing
rapidly in recent years, including approximately 52&nbsp;million reported to have high TG levels, a substantial portion of whom might be able to benefit from VASCEPA </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Plans to submit application for regulatory approval through Amarin&#146;s commercial partner in the Peoples&#146;
Republic of China </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Anticipate inclusion of VASCEPA in the treatment guidelines in Chinese medical societies </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pursue opportunities for VASCEPA in untapped countries after approval and market access in Europe is secured,
with such approval and market access expected to enhance ROW positioning </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>R&amp;D and Medical Advancement </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">R&amp;D and medical advancement highlights from 2020 include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">EVAPORATE exploratory study results, as previously reported, reported 17% reduction in plaque volume in patients
with coronary atherosclerosis treated with VASCEPA </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Numerous other studies presented in support of the potential unique mechanism of action of VASCEPA
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In aggregate, Amarin supported over 40 scientific publications and presentations in 2020 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">CardioLink-19</FONT> exploratory study results, as previously reported,
evaluated a higher initial dose of VASCEPA and suggested VASCEPA could potentially have utility as a therapeutic option for mitigating <FONT STYLE="white-space:nowrap">COVID-19</FONT> effects in an <FONT STYLE="white-space:nowrap">out-patient</FONT>
setting </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">This pilot study was rapidly commenced and completed with results that exceeded expectations
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Additional <FONT STYLE="white-space:nowrap">COVID-19</FONT> investigational studies of VASCEPA were also
commenced in 2020 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Witnessed an increase to twelve (12)&nbsp;the number of medical societies globally that now include icosapent
ethyl in their guidelines or have otherwise recommended its use </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">R&amp;D and medical outlook includes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Supporting approval of VASCEPA in Europe and regulatory review processes initiated by Amarin&#146;s commercial
partner in the Peoples&#146; Republic of China </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Supporting cost-effectiveness studies and market access for VASCEPA wherever it is approved
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Support completion of <FONT STYLE="white-space:nowrap">COVID-19</FONT> investigational studies and, based on the
results, decide on appropriate next steps </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Continue to study and differentiate the unique clinical and biological effects of VASCEPA </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In concert with Amarin&#146;s business development and other efforts, prioritize and execute on potential
opportunities to expand indications for VASCEPA or develop new products </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Financial Resources </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin reiterates that it believes its current cash resources are adequate to support the European launch and its planned operations and priorities in the
United States and globally. Such guidance included anticipated resources likely needed to further expand its VASCEPA supply capacity in anticipation of launches of VASCEPA in Europe, China and other countries as well as the opportunity to continue
to grow prescription levels in the United States after <FONT STYLE="white-space:nowrap">COVID-19</FONT> recedes, continuing the launch of VASCEPA for <FONT STYLE="white-space:nowrap">P-CVR</FONT> as commenced in 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Currently, Amarin anticipates 2021 operating expenses of approximately $550&nbsp;million to $600&nbsp;million which represents an increase of approximately
10% to 20%, compared with 2020 levels. Included in these anticipated expenses are increased costs associated with Amarin&#146;s commercial launch preparations and initial launch in Europe as well as continued U.S. promotional activities, including
increased face to face interactions between Amarin&#146;s sales professionals and health care providers and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising in the U.S. after the impact
of <FONT STYLE="white-space:nowrap">COVID-19</FONT> becomes less pronounced and <FONT STYLE="white-space:nowrap">at-risk</FONT> patients begin returning to their doctors for <FONT STYLE="white-space:nowrap">non-urgent</FONT> medical care. With
continued investment in consumer and <FONT STYLE="white-space:nowrap">in-person</FONT> marketing, Amarin expects VASCEPA revenue growth in the U.S. As described above, these spending levels may vary from quarter to quarter. Further these operating
expense levels assume substantial societal recovery in 2021 from <FONT STYLE="white-space:nowrap">COVID-19</FONT> and the continued limited availability of supply to the generic companies. Amarin will
<FONT STYLE="white-space:nowrap">re-evaluate</FONT> its planned spend in 2021 if any of these assumptions change. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>More Information to Follow
</U></I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin expects to provide further details regarding its 2020 results and perspective regarding its future outlook in the company&#146;s annual
report on <BR>Form <FONT STYLE="white-space:nowrap">10-K.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Amarin </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin Corporation plc is a rapidly growing, innovative pharmaceutical company focused on developing and commercializing therapeutics to cost-effectively
improve cardiovascular health. Amarin&#146;s lead product, VASCEPA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl), is available by prescription in the United States, Canada, Lebanon and the United Arab Emirates. VASCEPA
is not yet approved and available in any other countries. Amarin, on its own or together with its commercial partners in select geographies, is pursuing additional regulatory approvals for VASCEPA in China, Europe and the Middle East. For more
information about Amarin, visit <U>www.amarincorp.com</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Cardiovascular Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cardiovascular disease in an enormous and growing public burden globally. In the United States alone there are 605,000 new and 200,000 recurrent heart attacks
per year (approximately 1 every 40 seconds), in the United States. Stroke rates are 795,000 per year (approximately 1 every 40 seconds), accounting for 1 of every 19 U.S. deaths. Cardiovascular disease results in 859,000 deaths per year in the
United States.<SUP STYLE="font-size:85%; vertical-align:top">1</SUP> In aggregate, there are more than 2.4&nbsp;million major adverse cardiovascular events per year from cardiovascular disease or, on average, one every 13 seconds in the United
States alone. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Controlling bad cholesterol, also known as <FONT STYLE="white-space:nowrap">LDL-C,</FONT> is one way to reduce a patient&#146;s risk for
cardiovascular events, such as heart attack, stroke or death. However, even with the achievement of target <FONT STYLE="white-space:nowrap">LDL-C</FONT> levels, millions of patients still have significant and persistent risk of cardiovascular
events, especially those patients with elevated triglycerides. Statin therapy has been shown to control <FONT STYLE="white-space:nowrap">LDL-C,</FONT> thereby reducing the risk of cardiovascular events by
<FONT STYLE="white-space:nowrap">25-35%.</FONT><SUP STYLE="font-size:85%; vertical-align:top">2</SUP> Significant cardiovascular risk remains after statin therapy. People with elevated triglycerides have 35% more cardiovascular events compared to
people with normal (in range) triglycerides taking statins.<SUP STYLE="font-size:85%; vertical-align:top">3</SUP><SUP STYLE="font-size:85%; vertical-align:top">,</SUP><SUP STYLE="font-size:85%; vertical-align:top">4</SUP><SUP
STYLE="font-size:85%; vertical-align:top">,</SUP><SUP STYLE="font-size:85%; vertical-align:top">5</SUP> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About
<FONT STYLE="white-space:nowrap">REDUCE-IT</FONT><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> was a global cardiovascular outcomes study designed to evaluate the effect of VASCEPA in adult patients with <FONT
STYLE="white-space:nowrap">LDL-C</FONT> controlled to between <FONT STYLE="white-space:nowrap">41-100</FONT> mg/dL (median baseline 75 mg/dL) by statin therapy and various cardiovascular risk factors including persistent elevated triglycerides
between <FONT STYLE="white-space:nowrap">135-499</FONT> mg/dL (median baseline 216 mg/dL) and either established cardiovascular disease (secondary prevention cohort) or diabetes mellitus and at least one other cardiovascular risk factor (primary
prevention cohort). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">REDUCE-IT,</FONT> conducted over seven years and completed in 2018, followed 8,179 patients at over
400 clinical sites in 11 countries with the largest number of sites located within the United States. <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> was conducted based on a special protocol assessment agreement with FDA. The design of the <FONT
STYLE="white-space:nowrap">REDUCE-IT</FONT> study was published in March 2017 in <I>Clinical Cardiology.</I><SUP STYLE="font-size:85%; vertical-align:top">6</SUP> The primary results of <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> were
published in <I>The New England Journal of Medicine</I> in November 2018.<SUP STYLE="font-size:85%; vertical-align:top">7</SUP> The total events results of <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> were published in the <I>Journal of the
American College of Cardiology</I> in March 2019.<SUP STYLE="font-size:85%; vertical-align:top">8</SUP> These and other publications can be found in the R&amp;D section on the company&#146;s website at www.amarincorp.com. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About VASCEPA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl) Capsules </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VASCEPA (icosapent ethyl) capsules are the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-and-only</FONT></FONT> prescription
treatment approved by the FDA comprised solely of the active ingredient, icosapent ethyl (IPE), a unique form of eicosapentaenoic acid. VASCEPA was initially launched in the United States in 2013 based on the drug&#146;s initial FDA approved
indication for use as an adjunct therapy to diet to reduce triglyceride levels in adult patients with severe (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>500 mg/dL) hypertriglyceridemia. Since launch, VASCEPA has been prescribed over eight million
times. VASCEPA is covered by most major medical insurance plans. The new, cardiovascular risk indication for VASCEPA was approved by the FDA in December 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indications and Limitation of Use </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VASCEPA is indicated: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary
revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 150 mg/dL) and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">established cardiovascular disease or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diabetes mellitus and two or more additional risk factors for cardiovascular disease. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As an adjunct to diet to reduce TG levels in adult patients with severe
(<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>&nbsp;500 mg/dL) hypertriglyceridemia. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The effect of VASCEPA on the risk for
pancreatitis in patients with severe hypertriglyceridemia has not been determined. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Important Safety Information </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or
any of its components. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring
hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic
reaction to VASCEPA. Patients with such allergies should discontinue VASCEPA if any reactions occur. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">VASCEPA was associated with an increased risk (12% vs 10%) of bleeding in a double-blind, placebo-controlled
trial. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel or warfarin. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Common adverse reactions in the cardiovascular outcomes trial (incidence
<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>3% and <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>1% more frequent than placebo): musculoskeletal pain (4% vs 3%), peripheral edema (7% vs 5%), constipation (5% vs 4%), gout (4% vs 3%), and atrial
fibrillation (5% vs 4%). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Common adverse reactions in the hypertriglyceridemia trials (incidence &gt;1% more frequent than placebo):
arthralgia (2% vs 1%) and oropharyngeal pain (1% vs 0.3%). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Adverse events may be reported by calling
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-855-VASCEPA</FONT></FONT> or the FDA at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-FDA-1088.</FONT></FONT></FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents should be monitored for
bleeding. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Key clinical effects of VASCEPA on major adverse cardiovascular events are included in the Clinical Studies section of the
prescribing information for VASCEPA as set forth below: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Effect of VASCEPA on Time to First Occurrence of Cardiovascular Events in
Patients with </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Elevated Triglyceride levels and Other Risk Factors for Cardiovascular Disease in
<FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>VASCEPA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Placebo</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>VASCEPA</B><br><B>vs Placebo</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>N =<BR>4089</B><br><B>n&nbsp;(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Incidence<BR>Rate</B><br><B>(per 100<BR>patient<BR>years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>N&nbsp;=&nbsp;4090</B><br><B>n&nbsp;(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Incidence<BR>Rate</B><br><B>(per 100<BR>patient<BR>years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Hazard&nbsp;Ratio<BR>(95% CI)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="20"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Primary composite endpoint</B></P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cardiovascular death, myocardial infarction, stroke, coronary revascularization, hospitalization
for unstable angina <FONT STYLE="white-space:nowrap">(5-point</FONT> MACE)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">705<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(17.2</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">4.3</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">901<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(22.0</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">5.7</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">0.75<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(0.68,&nbsp;0.83</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&nbsp;</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>VASCEPA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Placebo</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>VASCEPA</B><br><B>vs Placebo</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>N =<BR>4089</B><br><B>n&nbsp;(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Incidence<BR>Rate</B><br><B>(per 100<BR>patient<BR>years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>N&nbsp;=&nbsp;4090</B><br><B>n&nbsp;(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Incidence<BR>Rate</B><br><B>(per 100<BR>patient<BR>years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Hazard&nbsp;Ratio<BR>(95% CI)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="20"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Key secondary composite endpoint</B></P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cardiovascular death, myocardial infarction, stroke
<FONT STYLE="white-space:nowrap">(3-point</FONT> MACE)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">459<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(11.2</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">2.7</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">606<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(14.8</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">3.7</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">0.74<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(0.65,&nbsp;0.83</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="20"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other secondary endpoints</B></P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fatal or <FONT STYLE="white-space:nowrap">non-fatal</FONT> myocardial infarction</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">250<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(6.1</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">355<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(8.7</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">2.1</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">0.69<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(0.58,&nbsp;0.81</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Emergent or urgent coronary revascularization</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">216<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(5.3</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">321<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(7.8</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">1.9</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">0.65<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(0.55,&nbsp;0.78</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cardiovascular death <SUP STYLE="font-size:85%; vertical-align:top">[1]</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">174<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(4.3</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">213<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(5.2</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">1.2</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">0.80<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(0.66,&nbsp;0.98</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hospitalization for unstable angina
<SUP STYLE="font-size:85%; vertical-align:top">[2]</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">108<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(2.6</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">0.6</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">157<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(3.8</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">0.9</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">0.68<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(0.53,&nbsp;0.87</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fatal or <FONT STYLE="white-space:nowrap">non-fatal</FONT> stroke</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">98<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(2.4</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">0.6</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">134<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(3.3</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">0.8</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">0.72<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(0.55,&nbsp;0.93</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="20" VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">[1]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes adjudicated cardiovascular deaths and deaths of undetermined causality. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">[2]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Determined to be caused by myocardial ischemia by <FONT STYLE="white-space:nowrap">invasive/non-invasive</FONT>
testing and requiring emergent hospitalization. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FULL VASCEPA <U>PRESCRIBING INFORMATION</U> CAN BE FOUND AT <U>WWW.VASCEPA.COM</U>.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release
contains forward-looking statements, including statements regarding revenue and prescription growth, the impacts of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> including its future trajectory and effects on
<FONT STYLE="white-space:nowrap">non-urgent</FONT> medical care, the impacts of generic competition, including expected levels of generic supply, changes to U.S. commercial operations, including to spending and promotional levels, plans for
commercial and international expansion, including the timing and outcome of regulatory approvals, market access negotiations and commercial launch, R&amp;D and medical outlook, including the timing and results of future studies, market access
efforts and indication expansion opportunities, the adequacy of its current cash resources and its 2021 operating expenses. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties.
Amarin&#146;s ability to effectively commercialize VASCEPA will depend in part on its ability to continue to effectively finance its business, efforts of third parties, its ability to create market demand for VASCEPA through education, marketing and
sales activities, to achieve broad market acceptance of VASCEPA, to receive adequate levels of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reimbursement from third-party payers, to develop and maintain a consistent source of commercial supply at a competitive price, to comply with legal and regulatory requirements in connection with
the sale and promotion of VASCEPA and to secure and maintain patent protection for VASCEPA. Among the factors that could cause actual results to differ materially from those described or projected herein include the following: uncertainties
associated with the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and generic competition; factors outside of our control may prevent VASCEPA from achieving market acceptance and commercial success; the commercial value of VASCEPA
outside the United States may be smaller than we anticipate; uncertainties associated generally with research and development, clinical trials and related regulatory approvals; and sales may not meet expectations and related costs may increase
beyond expectations. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin&#146;s filings with the U.S. Securities and Exchange Commission, including its most
recent Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q.</FONT> Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes
no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. Amarin&#146;s forward-looking statements do not reflect the potential impact of
significant transactions the company may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements that Amarin may enter into, amend or terminate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Availability of Other Information About Amarin </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors
and others should note that Amarin communicates with its investors and the public using the company website (<U>www.amarincorp.com</U>), the investor relations website (<U>investor.amarincorp.com</U>), including but not limited to investor
presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a
result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time
to time on Amarin&#146;s investor relations website and may include social media channels. The contents of Amarin&#146;s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed
incorporated by reference in any filing under the Securities Act of 1933. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amarin Contact Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investor Inquiries: </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin Corporation plc </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In U.S.: +1 (908) <FONT
STYLE="white-space:nowrap">719-1315</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>IR@amarincorp.com</U> (investor inquiries) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Solebury Trout </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>amarinIR@troutgroup.com </U></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Media Inquiries: </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin Corporation plc </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In U.S.: +1 (908) <FONT STYLE="white-space:nowrap">892-2028</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>PR@amarincorp.com</U> (media inquiries) </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">American Heart Association. Heart Disease and Stroke Statistics&#151;2020 Update: A Report From the American
Heart Association. <I>Circulation</I>. 2020;141:e139&#150;e596. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ganda OP, Bhatt DL, Mason RP, et al. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia
management. <I>J Am Coll Cardiol</I>. <FONT STYLE="white-space:nowrap">2018;72(3):330-343.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Budoff M. Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease.
<I>Am J Cardiol</I>. <FONT STYLE="white-space:nowrap">2016;118:138-145.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Toth PP, Granowitz C, Hull M, et al. High triglycerides are associated with increased cardiovascular events,
medical costs, and resource use: A real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. <I>J Am Heart Assoc</I>. 2018;7(15):e008740. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">5</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease - New insights from
epidemiology, genetics, and biology. <I>Circ Res</I>. <FONT STYLE="white-space:nowrap">2016;118:547-563.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">6</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Bhatt DL, Steg PG, Brinton E, et al., on behalf of the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT>
Investigators. Rationale and Design of <FONT STYLE="white-space:nowrap">REDUCE-IT:</FONT> Reduction of Cardiovascular Events with Icosapent Ethyl&#150;Intervention Trial. <I>Clin Cardiol</I>. <FONT STYLE="white-space:nowrap">2017;40:138-148.</FONT>
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">7</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Bhatt DL, Steg PG, Miller M, et al., on behalf of the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT>
Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. <I>N Engl J Med</I>. <FONT STYLE="white-space:nowrap">2019;380:11-22.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">8</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Bhatt DL, Steg PG, Miller M, et al., on behalf of the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT>
Investigators. Reduction in first and total ischemic events with icosapent ethyl across baseline triglyceride tertiles. <I>J Am Coll Cardiol</I>. 2019;74:1159-1161. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>amrn-20210107.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-7 Build:20201110.1 -->
<!-- Creation date: 1/7/2021 8:48:36 AM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2019-01-31"
  xmlns:amrn="http://www.amarincorp.com/20210107"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.amarincorp.com/20210107"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amrn-20210107_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amrn-20210107_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.amarincorp.com//20210107/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>amrn-20210107_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-7 Build:20201110.1 -->
<!-- Creation date: 1/7/2021 8:48:36 AM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Three</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Three</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Country</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Country</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>amrn-20210107_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-7 Build:20201110.1 -->
<!-- Creation date: 1/7/2021 8:48:37 AM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amarincorp.com//20210107/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="amrn-20210107.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com//20210107/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine3" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g281965g0107072404599.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g281965g0107072404599.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] 2\# 2(  A$! Q$!_\0
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MPZ$$9!J6N,Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HK!U76]4L+WR+3PW>ZA%L#>?%-$J
MY],,P/%9S>*O$ ) \#:F?^WJ#_XJJ46Q71U]<UX\\2+X7\)W=^&'VAAY5NI[
MR-P/RZ_A5,^+/$@''@/43_V]P_XUYWK>KZOX\\;V=J/#MR]OHS>9<Z>)TW%\
M]VSM]!CZU<(7=WL3*6FAKP?#9KGX2?9Y$SK4Q_M .WWC(1PI/NO'U->($$$A
M@00<$'J#7U&/$?B$C_D2KT?6\@_^*KQ;XH^&Y-'U^/4EMFM[?4U\XQ$@^5+_
M !ID<>_YUT49OF:?4RJ15KH[SX+>*?MNE2^'[F3,]G\]OD\M$3R/P/\ .O5Z
M^1O#NMW'AW7[/5+<G= ^67^^IX9?Q%?6%A?0:EI]O>VKAX)XQ(C#N"*QQ$.6
M5UU+I2NK%FO.?%/B?QWX:@NK]M'T>;38G.)$E<N$SP6&1^.*]&KDOB8,_#S6
M/^N)-9PMS),N6QYC_P +UU__ *!6F_G)_C7JW@;Q4OB_PY'J#(D5RK&.>)#P
MK#TSV(KY\\1^'#INAZ%J\*$6]_;?.1T$H)_F/Y5O?"'Q+_8WBG^SYY-MKJ V
M<G@2#[I_I^-=-2E%PO%&,9R4K2/HJF2R)#$\LC!412S$]@*?7!_$_5YX='M]
M"L"3J&KR"WC"]0A^\:Y8QYG8W;LKG$7_ ,<]5CU"X2QTRP>U60K$\A?<RCN<
M&M/PU\2?&OBRZEM]*T72&:%=TC2R.JJ.W>O,?&FDPZ%XHN-,MU 2W2->.YV\
MG\37?_ ?_D(ZQ_UR3^==<X05/F2,(RDY6;/9=.:];3X6U%(4O"O[U8"2@;V)
MYQ5DD $DX ZDTM<[XYU:TT?P?J%Q>*'1HC&L9.-[-P!7&E=V-WHCD/$OQ@LM
M,\16MAIHCNK:.7;>S]0!TPA[D>M>FP3QW,$<\+AXY%#*P[@U\>7=E<V$_D7<
M#P2[0^QQV(R*]R^#7BO[?I;Z#=29N+0;H2QY:/T_"NFK148WB90J-NS/5:Q]
M>E\00PQ-H%K87$FX^:MW*R#';! /-;%%<R-CQ/5/C+XBTC4;C3[S0K".Y@;:
MZB9F /U%7?#?Q%\;>+YKB+2-+T4-;@,XF>0<'TYKSKXD#'Q"UC_KM_2NT^!'
M_(3U?C_EDG\S79*$%3YDCG4I.5KFWJ_C;XA>&H?M.K>&-/DM%/S36TC%5^I!
M./Q%6O#WQHT359TMM3@DTR9R KNP>(G_ 'NWXBO2)H8YX7AE0/&ZE65AP0>H
MKY$UVUBLM>U"UAQY,5PZ)] :SI1A4NFK%3<H:W/KQ75T#HP92,@@Y!KAO%>O
M>-M!6]O[32](N-*M_F#-*_F[?4C@?E6?\%=3NKWPE-;W#LZVDYCB9CG"X!Q^
M&:ZCQ[_R(FL_]>S5ER\L^5EWO&YY/_PO77_^@5IOYR?XUV.A^)?B-K^F1ZA:
MZ'HD5O*-T1GFD4N/4 $\?6OGO^'\*^JO '_(A:+_ ->J?RK>M&,%=(SIR<GJ
MSA_$GQ"\=>$_).K:#I*1S$B.2*5W4D=1UX-8 ^.NO9&=)TTCN 9/\:Z3XX -
MI^A*0"#>$$'N.*XSXC?#N3PVXU;3(V?29<%E')MV/8_[)['\**:IM+F6X2<D
MW9GMWA7Q38>+-'2_LFPWW9H6/S1/W!_Q[UN5\F>%O%%_X3UA-0L6W*?EF@)^
M65/0^_H>U?3OAWQ#8>)M'AU'3Y-T;\,I^]&W=6'8BLJM)P=UL7"?,CEO$OB'
MQWH,%W>Q:%I=S80,Q#QSNT@C'\3+QVZXK&\+^/O''B\R/IFAZ2+>%@LLTTKJ
MH/H.<DXKTW5,?V1>Y (\A^#_ +IK@_@F,>  ?6[E/\J$UR-V!I\UKFWK7BJY
MMK][+3X8?W+I%-<31R2#S67<(T2,%F;;R3P ,5=\.>(CK&^"XCB2X6))T>!R
MT4\3YVR(2 >H(((R"*PO$&@SB_N!)97=YI5U=K>M]B(\Z.41F,J064[2,$,#
MD$$8Q6AX3TB]@F6^OH?L_E6<=C;0L%#^6I)+N%)568D?*"<8]ZEJ/*--W,[Q
M?;V,VLAKBT\6R.L2C=I)D$..?[I W>OX5SS6FD#_ )<_B*/HTO\ C70>,=0L
M+36E2Z\7ZOI+F%2+>TMRZ8R?FSY;<GZ]JYMM<TD'_DIGB ?6R/\ \:JXWM_P
MY,K7,[6[K1M,TJ>XV>/;>4*5B:ZFDCC+D?*"Q/K5+PEH]M!I0N=4T?QC)?7+
M&1Y[!71'4\KR&!;UR?6LWQ!J4&N>(+/2Y/%6JZEHT9$LUQ+;DE&Y^ZBKD\8&
M2.IKKH]8TI=H'Q"\4 #M]B./_15:NZC8A6;-;2M.TRXO[>%+'QU 6< 27,TR
MQKW^8[^E=3XZ\-)XI\+75A@"X4>9;M_=D'3\^GXUF^"YK:_OIY[3Q5K&JK"F
MUX;V'RT&[H>44D\'O7;USRDU+T-4DT?&CQO%(\4B%)$8JZD<J1P17M?P3\4^
M=;3^'+F3YX<RVN3U7^)?P//XFN:^,7A@Z1XD75K>+%IJ'+D#A91U_,<_G7#:
M+JUQH6LVFIVK8EMY X']X=P?8BNV256GH8*\)'U]7*_$@9^'NLC_ *=VK=TG
M4[?6-*M=1M6W0W$8=?;/;Z@\5@?$M]GP\UDYQF BN"/Q(Z)?"8-OX=3Q-\%;
M&QP//%KYD!]'!)%?/ZM+;3AANCFB?Z%6!_QKZD^'O_(@:+_U[C^9KQ7XL^&_
M[#\6M=PIBUU &5<#@/\ Q#^M=5&?O.+,JD?=3/;?!?B./Q)X3M=29QYH39<#
M/W77K_C^-<KX54^,/B#J/B>4%K'3R;2QST)_B8?Y]*\F\+^*-3TFPU'1;!6=
MM4411X/*.3C(_ FOHWPKH47AOPW9:9$!F)!YA_O.?O'\ZSJ1]G?S*B^>Q\\_
M$_\ Y*+JO^\O_H(KL/@/_P A'6/^N2?SKC_B?_R475O]Y?\ T$5V'P'_ .0C
MK'_7)/YUM/\ @F<?XA[?7EOB#/CCXD6F@1Y;3-)Q/>$=&?LM=MXO\01>&O#5
MWJ4A&]$VQ+_><]!7E7@/Q_X9\,Z7.^H-?2:I>2F:ZD6W)&3T .>E<].+LY)&
MLVKV9K?&?PH+G38=>M(AYEJ!'.%'6/L?PKQ_0-9N/#^N6NJ6Q.^!P6 _B7N/
MRKW"\^,'@R]LYK6X34&AF0HZFUZ@_C7@=X+47TXLG=[7>?*9UVMM[9%=%'FY
M>62,JEKW1]=Z5J5OJ^EVVH6K!H9T#J1[]JN5XG\%?%?E32^&[J3Y7S+:DGO_
M !+_ %KVRN2I!PE8WC+F5SY<^)/_ "4+6/\ KK_2MOX3^)(/#MUJ<D]CJ-T)
M40#[%;F4K@GKCI6)\2?^2A:Q_P!=?Z5VWP''^EZR?]B/^9KLG;V.ISQ_B%SQ
M'\;K86DMMH>GW2W3 KYMVH01'_=R23]<5YYX:\#:YXSF>>U>W$1?,T\LRY4G
MJ2H^;]!7H/QF\'[XE\2V47SIA+M5'4=G_H:\N\+^)+SPKKD.I6C$@';-%GB5
M.X/]*5-+DO3W'-OFM(^E_"7A>T\):%%IMJQD(.Z65A@R.>IJ'Q[_ ,B)K/\
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86RQR>@%;SJ\\+/<SC#EE=&S1116!H?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>d281965d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="amrn-20210107.xsd" xlink:type="simple"/>
    <context id="duration_2021-01-07_to_2021-01-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
        </entity>
        <period>
            <startDate>2021-01-07</startDate>
            <endDate>2021-01-07</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2021-01-07_to_2021-01-07"
      id="Hidden_dei_EntityRegistrantName">AMARIN CORP PLC\UK</dei:EntityRegistrantName>
    <dei:EntityTaxIdentificationNumber
      contextRef="duration_2021-01-07_to_2021-01-07"
      id="Hidden_dei_EntityTaxIdentificationNumber">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressPostalZipCode
      contextRef="duration_2021-01-07_to_2021-01-07"
      id="Hidden_dei_EntityAddressPostalZipCode_duration_2021-01-07_to_2021-01-07">2</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="duration_2021-01-07_to_2021-01-07"
      id="Hidden_dei_CityAreaCode">353 (0)&amp;#160;1</dei:CityAreaCode>
    <dei:AmendmentFlag contextRef="duration_2021-01-07_to_2021-01-07">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2021-01-07_to_2021-01-07"
      id="Hidden_dei_EntityCentralIndexKey">0000897448</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2021-01-07_to_2021-01-07">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2021-01-07_to_2021-01-07">2021-01-07</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2021-01-07_to_2021-01-07">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2021-01-07_to_2021-01-07">0-21392</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2021-01-07_to_2021-01-07">77 Sir John Rogerson&#x2019;s Quay</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2021-01-07_to_2021-01-07">Block C</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="duration_2021-01-07_to_2021-01-07">Grand Canal Docklands</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="duration_2021-01-07_to_2021-01-07">Dublin 2</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="duration_2021-01-07_to_2021-01-07">2</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="duration_2021-01-07_to_2021-01-07">IE</dei:EntityAddressCountry>
    <dei:LocalPhoneNumber contextRef="duration_2021-01-07_to_2021-01-07">6699 020</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2021-01-07_to_2021-01-07">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2021-01-07_to_2021-01-07">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2021-01-07_to_2021-01-07">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2021-01-07_to_2021-01-07">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2021-01-07_to_2021-01-07">American Depositary Shares (ADS(s)), each ADS representing the right to receive one (1)&#160;Ordinary Share of Amarin Corporation plc</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2021-01-07_to_2021-01-07">AMRN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2021-01-07_to_2021-01-07">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2021-01-07_to_2021-01-07">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140293097580184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 07, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AMARIN CORP PLC\UK<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">353 (0)&#160;1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000897448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan.  07,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">X0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-21392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">77 Sir John Rogerson&#8217;s Quay<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Block C<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Grand Canal Docklands<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Dublin 2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">6699 020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">American Depositary Shares (ADS(s)), each ADS representing the right to receive one (1)&#160;Ordinary Share of Amarin Corporation plc<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMRN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M;<J(<"4[A3K==K/90;"Z.587%<N-9[Y)2D.&-^]<8(O-=0K[<X[#F##%I;7
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M]B/#MF!DDAWL%](8&6>7(:.PQFP%>+Z4TKP5[+>"_%-/_U]02P,$%     @
M #(G4H.II0/4 0  ,@8   T   !X;"]S='EL97,N>&ULU57;BM1 $/V5IC_
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MX_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0
M   (   R)U('04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @  #(G4H@0L(7O    *P(  !$
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M;',O+G)E;'-02P$"% ,4    "   ,B=2'#AEZC\!   \ @  #P
M    @ '@#P  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @  #(G4B0>FZ*M
M    ^ $  !H              ( !3!$  'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @  #(G4F60>9(9 0  SP,  !,
M ( !,1(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  >Q,
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d281965d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com//20210107/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d281965d8k.htm">d281965d8k.htm</File>
    <File>amrn-20210107.xsd</File>
    <File>amrn-20210107_lab.xml</File>
    <File>amrn-20210107_pre.xml</File>
    <File>d281965dex991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d281965d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d281965d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "amrn-20210107_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "amrn-20210107_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "amrn-20210107.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 6,
    "total": 6
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "amrn",
   "nsuri": "http://www.amarincorp.com/20210107",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d281965d8k.htm",
      "contextRef": "duration_2021-01-07_to_2021-01-07",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.amarincorp.com//20210107/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d281965d8k.htm",
      "contextRef": "duration_2021-01-07_to_2021-01-07",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20210107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20210107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20210107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20210107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20210107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20210107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three",
        "terseLabel": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20210107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20210107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20210107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20210107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20210107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20210107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20210107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20210107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20210107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20210107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20210107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20210107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20210107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20210107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20210107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20210107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20210107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20210107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-21-003641-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-21-003641-xbrl.zip
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M02;KD]S>]">^N6HV#O[\%U!+ P04    "   ,B=2N<YL>IL&   )2@  %0
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M#T&7\T@G*A=>6,-7'R4!&B3K0E:_J^@_%_&"O/%,2:ZHWVBD\7AZ3WVW[YJ
M2>?KCC_==JZ;G7SC]N:F?M=M5N,/GW?=T30S"X]$?P196JRH+88"+9^-0@$I
M%8Q2(2-N24/;5YWPJ10B7&:'J<#Q]2FL6[!.41D0SRV^2\Q/0X YQ(8"V:02
M=[H+0WWKDJP+OT=+ FL(+U0 -I$23Q\NDV"<*1ADZKI@02U]],%'V\D</@I#
M=0!G0+^0#+APA$]$X#M"?"(':#OQY%3)N+C3(#LA2/V=>7%8('6PY5YR]&&F
M$T8[_4"Z7 T!*8B&6&CL,:@8\A[W2:52, M/7%P-+WD_EXJ+PJP_5R']<;B5
MJ]T#XMQ-WB2'L9<_Y"HZ!)1:0MK7H H0E'ZBAN#0M?_K,8C?P*W:,<WZW&%V
M1"OM]P "Y%U,2]RLMSI?,_8Z0OK14>A<T_Q)=X[9<Y3<ZWD$ITI4T/L+)D7T
M<:##:8\[X51Z<NH3%2)5@/4!W8&OKC/!=4VOX<"T$!<D;U5":E$WO#L4G999
M4@07F4<0HC VO2Q]*$L%D(0"PHK]'> 5_ AV=(L8K(B30D)IR&D>KF*:7F_"
MXP)9]2(.<_M+MV_>(O$6E8)A?KG>8NH3])TYW$@*;69DSM0>/,2!?9A,/V](
M7_-VSVZD.Y2YROGR?1>,^Z*]E^B#'1(\?EIGEV3)!DTT>_F5=TG6WN&(U20.
M<".^7_8D!,5M4=BT;K2T>K3^GLLU4Y;D7GA9-";9E$<9DKBX_OBL*[9D()-J
MAE #91%(4'KE6U>+QBB3'!C/O!07PA(=)>&[&.W2N5DY/;'9N%(Q"T-_I#>Y
MI['7$;&UJ\X*'\%.T*7D^UI891K'+\JIAH!OR1VLD+107:FE+W9<4Y\2?8'V
M@(UZS,8H#J-B'7-B5\SE";[?F-C1"X4.TYJUHJ2Y@W@Y:Z/E7P3_1OEZJAR@
M]?RKK@GL]6)EM_6^7;__O=/LOG@.E7[O6%@%_#O@,HJ!ULU<,LJ'=@!QO$4#
M+/FEDRZ8!K(.!:N%!A&^,*C'(-/J8_:!@'26$77 W#)P88P&!\P9"@D+LQ=R
MRR\U))HYBY(9!<T=+CN)@YA-XJ*GKSIO!/&I8RB[1^UD)F1;C#]>R=&$[Y.K
M9CK='6SJ908$+P)VZKW+R]\ZMGW\@+KW5 "AVQ<CB)?JN[_(Y*7X]U)@?YI4
M7PCR9N=(5NQ>;.C;BJH8OCG@78'<@RL1KWZ(Y,N7C!<".\>6-Y;L'RRFF?IU
M];KTU1ARUH=P+[ZX?JLOKLO,E"4C=[@LZO^8Y%+_MR6U_P-02P,$%     @
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M.\,Q+_C=-GX%%&LU_*5YL[3D^@$D'HW+\AG0<@8J F'AB2DOQAPM_5$53MK
MPCH-9V&+_0AJ=]IHR'O:7-+!BS1^>?CF],0U]>;C^?')>1-H\_3PT\7)KOLP
M=_C3<WTAN)G7+]HOQ-')Z>FGP^/CWH=WV=\7GPZ/W-]%NN?QG#.'$*_%BP)/
M >43!,NNO-:!;Q\\=B]W7^:3NCR>^G$=^,EOEJ&@4>:8"S,)Y.$[LU[K3+TV
MHX-B0^5G<7-*O]KE%>7-$7<#9\&5=LZ"S%(M:)&DPIM&R:3-_P1R,%9T6ST)
M 4'3@W_.\1\$1@GV%=">+]#>DG.N[!^QUD+!CRU !<W<,J#&L=U).MZ4_N;'
MZ<"PG@PF,$@*=+YH$Z!Q4*_I-(%F8$0F2?V I06Z#(!/HTYK<JGA.K9&M12A
MOD%.CP2!] #:X4CC:(&KFC$9&* )PW)$8)"E( QX(+/!7S'9 DXW'@'\:S\&
M^!W(<L.:!++/+I*E]1(TU SCE, 8@+81D(O F?#U6C]-'"6!H:[ 6,H\]E.C
M0) K%5= KICX?3@&T_U^M))9G%O%OCNN1,?7'VG@?06<#F0,^K-B]1K8.2CL
M"6@2,3D9\3L8Z5>5U&OHDBAY&7?67Q;5E))R(OKD@]>L@Y/LL$S?EXG,Y030
M7&K0;]_[]V^]0Z".6)$0RE09)I4X&(03#]1\7XF5RW>K3DOJ*Z ]T6VWQ6CP
MRC^M%)^*9N8I/M9'Q=Y<0-^(W- ^^PX]=*;"GR4ER$]CU$7R,Q7I^X'50< L
MCM$<Y2.N0:SP_%?365X''3$5]Z[4D+N@>)&2TY_/*LD?BR?ZSD%J]8,@]IO(
MB2=@W<EP K]FQT+DORPX6?OX/C!9=76%40'7JD$6(394KSD7^2"%O0@QH@$#
M.8 ?D[_?MS$&Y)TPP9_ 6R6&. CR9+AWC?8"E:#^7@&[8K%WXOI8IWT,'<&O
M4#DP,N1S"0\$=Q)+T(_I*"&VH02.$X,BG(Y)F_8X1(N#C\YD[ V9^_Z> KS9
M'5VOL4<1%VMS#UZ!G\#$C&&4'C:?*#FBMA*%GDL.$0!>3=&5R*01Z4!N>-:'
MS]^K1\&*X/&%CIPN-5(*WS1+VPVKKH5*4ZG(Z&XR.O3EV*K'2YND /1$>SJT
MNO,UP%^G2 LAO(GDV.#/K->3IR4"*_4ZB!.,&</3.K82V)9%86+0&426*Q*5
MH^(LP,<^ X,U\@HM SS_C:5G!=DPCSR#L5TI.E^4.#XZPQYK^ *C1^X5+(_B
MJZ_7"LYZ;<][K'_>5 [ZBB@SHL2P28R"\&Q0@(UH(E_]MY[Z Q&-@)Q$&B6P
M](FU(+BU+(CX7M.>8TK2T <!&:FK(&$1Y_3#2F.K4#WWV&D0D4UK88W^]&_&
ML\?!E[[V$@#R=6 P' XQK6.?PG.!WZ(D<"Y/=([BWQ@C!Y(CC^V!3PF%IW!3
MW$@$-K:SUT$4+2T;*=0$'5%^9<A4%OI\%<SS"+(#1")Y)QL.Y0[6>"IFS6..
M@3,%[CT'E9&.F@I4C@'(DHF%9FZE$[C)$>KKFVC*Y[K5?HFD<S@&F\:=7)"'
M"MVL0"Z#8;*0.+H5V<VZ(L_+).@!"">%6#=L'SY>)1CGUXO$,= 0Q6'8T'\,
M5^,X;0KP%F:,,:\8X[HTC7KH$;FUUD-YC3&T+KB[O"K=]LO26>6]?8+BVJ1^
M7:?L3VY59EDE*^<YD'48ZAL^G$:T$P6KI0BN$*-H#T1&T,G09/'E'#N+S*5>
MLZ&3=-B-O=I3#V0RGHH35!SA\\B43L?%BFH-6FSD(?%@;*U/5QH,^ZI7L7,E
MXS"[PU7)P4H.WH5Y\@+?"KT@-&8J6U^1FX'N@-A3$G37\<E(.K[! &,=DSRC
MSP1^,P;;25D]#\,%*="9H@W1=4 6S#?%";J 0)0(*F'-ML)XQ=;O5O6^P9*X
MEIX71(5(^\!0G#WH0J%V%T,X7&H$$,3+-0ANTEND-U0YP\_N@I9N%J!X&2E[
MF<AQ]L)I^T**9LE)<$/7"SR8>Q"E5J^5Z&<D/9:<@4R%=YM&/V!H_-K/'QK_
M<_"?YRQCW\V06!S@SL=@6=0[1XE%P!_X" UTSSB KC$:(0_O6;E\)_8_'_PR
M2/;P^D 6'K/*ESU-O5:\0&PY DEB#-$7)AV/H0>\3YT4PC--HKVO8XSZ+T;=
MNRMS5AGPK!>3KQ5"BS9.OY*_%?[G!&62\AB$03(1?"K,Z)2F<!%L/)3Q2'H8
M@L#![A.*>R=-TVF1\EH&H6T)X^,#SYYO 0[['$6,Y\[U6J4C5AA=,K(AS6P5
MX&AL?5,\3*P&DAV%WV2MC#6&_.#AH\,D\]^&BW+@^Y5%+HVZY5"']K*QN^&-
MT3T2W1'%^#5W"0J-N!1:"-F1)RB1 K+J6'@A] *$9V,UK?G%P9\&GS1IY2RO
M#*BY!M2TZZH$5XZR)%-F^G*<'JO8AI_EM^R=YY=/>?#^>C0D8&/T +12KY%O
M@-HJ-+!4^,##)#*@&YOV7G'QHN9C7A.UW577"BO:7/!\5Y(9<2PGHK/==E']
M6>ZS,SQVHIC00SJ/PAOWXN3LL"'0A([!V/RO\HN9+&+.D%;P14@0$?802B:<
M@,#>NOT7?.L#.DG< "E?21(_:-2@]P'M#=35R&2P[0*1>^A/<69'8"\!^+&\
M 8Y!8"]- +JJE+>*!N;*IRB/-"V'/5.8**DX/MY"*0'K@D*>)Y3\CVX\AGHP
M*:A[*6>SFKIW7J^MD&3J(]Y%)$?9Q<;5"J052.\&:2_+7(8H= '4^-FJ5Q36
MG&<"0@8Z=0I>2)SC3\5:8G FV!4Z3A:)+L/S<9>QJ&BL+'2PSBZ?/!Q5C:73
MT:9,$Z-"3&Y'>6GBZFY!12#WQ%\BW_98>Z#XXCPWIDR3H08SUEXPOP6LG&L[
M^-D3#^F1MH$JS(A\11;U8'Y'.G%*#:?2P[-V4$%(0U$^Q?][,H+'\E,@MK$I
M3D;81$SD'@WLY4G*K1*YRY;HDN*$BK(?!@;5M(H"*@JXDP+.,)'72/X.7%3Z
MUV@3$]I9MT&L4A!4-&G>X$59,S&)&I58?^99O9V!KJ#/9S*F7N,PS05B1!X\
M-M]*N2HBOZ*'N^GA(2+PYP3.%PBAXLO5X<#<; SHJXP5*PH9ML# -'@]*C(%
MQ1WSK T&J)$DJA2VFGGJG880XQ. ;5_)A'/!4O1\*?E.8"BM,J@1Z!($M:-"
M:L4QYW@#;V>D585L__>&A5:AT!7+8VOL_=DGH<<!>5^+$ KO*1A1H:I"U9VH
M.CD[S!F3KSR.7\_@A;8^0&QS2_AR0FH?P3![L$)7)?SFF<]%ET^D!IKNMZ,!
M44SACA<F%KBW=.\#['V:-/N3IOUH;0]G@O2E"3B\=YR U&6O48;^2H^K&.6<
M!$)*?46/#]9X<'%NY*E4?Z3H[]>8Y@K=E#;HHO@<%UG17HH&R@)(ORN-7);C
M+<OQ2<G=,DNGP1D>N%(+]9R'(]'!6]Z BV*]?,=9/_GAK*>*KU=\_6Y:.&4/
M9A*0![\_L7[_">@%>%?)UJ\J._Q7@I9J84$OD\847.32O]UU2EN!K>*\'$P
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M E"G:E?D"CR6>HGHI("\,)^(_@P_6*^=JW$*JHQ'02]$L9427B%TSI57=P;
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M.=5$QCD6ZLPB*[)RS>;P+A:7E1&0:TL42GDN<-\Z5DT7(I'9M@7A3HN:S2T
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M\!OY.&:Z4EI+"H".9?[EH.^D7% F 3U.K+4VR@9R5@D,..DMD87:>E(8+*G
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M*I. )1YQWP)X!5TI@U3&$G;&=1!=Z_ :YI?V#5:8P+7#\G?\*ZRABI$V<?#
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M2P$"% ,4    "   ,B=20U^N.64#   K#   $0              @ $
M86UR;BTR,#(Q,#$P-RYX<V102P$"% ,4    "   ,B=2N<YL>IL&   )2@
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:+FAT;5!+!08     !0 % $ !  #F5      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
